Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
23 Dec 2022
Serine protease inhibition shows promise in COVID-19
The serine protease inhibitor upamostat appears to be beneficial in the treatment of COVID-19 outpatients, being generally tolerable and bringing a rapid resolution of severe symptoms while reducing the incidence of new ones, according to the results of a pilot study.
Serine protease inhibition shows promise in COVID-19
23 Dec 2022
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
22 Dec 2022
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
Exposure to dihydropyridine calcium channel blockers does not appear to put patients at increased risk of developing pancreatic cancer as compared with thiazide diuretics, as shown in a large study.
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
22 Dec 2022
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
Rapidly maximizing medications in patients discharged from hospital following acute heart failure (AHF) reduced the risk of hospital readmission or death at 180 days, according to results of the STRONG-HF* trial presented at AHA 2022.
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
21 Dec 2022
EMERALD updates highlight therapeutic potential of elacestrant for ER+/HER2– mBC
In the updated analysis of the phase III EMERALD trial, the next-generation oral SERD* elacestrant continued to show favourable signals for the treatment of ER+/HER2– metastatic breast cancer (mBC).